Leo Zeff's psychedelic-drug program for treating alcohol dependence

Leo Zeff's psychedelic-drug program for treating alcohol dependence is a named strand in the book's history of LSD treatment, but the supplied account offers little direct description of Zeff's own methods or results. Its significance is clearest in the larger dispute around alcoholism treatment: whether LSD's apparent benefits came from the drug alone, or depended on the human attention and supportive surroundings of a session. The book's references associate Zeff's program with Al Hubbard, while its account of the wider field shows how sharply treatment outcomes could change when the therapeutic setting changed.

Program and historical placement

The book's index directs readers to a discussion of LSD therapy for alcoholism on pages 148–52 and separately cross-references Zeff with Al Hubbard, including pages 167 and 170. These references identify the program and its place in the book's treatment of psychedelic practice, but do not, by themselves, establish the details of Zeff's role, the program's procedures, or its clinical outcomes. The account therefore supports a firm outline of the historical problem surrounding the program, not a detailed biography or a claim that Zeff conducted any particular trial.

That wider problem took shape around treatment at Weyburn hospital, where Humphry Osmond and Abram Hoffer found that many alcoholic patients described LSD experiences less as temporary psychosis than as transcendence or spiritual epiphany. Their observations unsettled the delirium tremens model they had initially used to understand the drug. After Aldous Huxley's mescaline experience, which he said bore little resemblance to psychosis, they also reconsidered whether states psychiatrists might label depersonalization, hallucination, or mania could instead be understood as mystical union, visionary experience, or ecstasy. This change in interpretation mattered to the treatment field in which Zeff's program is indexed: the experience was no longer necessarily treated as a temporary imitation of mental illness.

The treatment environment

Osmond and Hoffer also learned from volunteers that the surroundings of an LSD session could strongly influence what happened. They came to value an engaged, empathetic therapist, preferably one with personal experience of LSD, and suspected that some psychotic reactions might be artifacts of a metaphorical white room and a clinician in a white coat. Although the expression “set” and “setting” was not yet used in this context, their observations anticipated the principle later associated with Timothy Leary's work at Harvard: the circumstances of a session were part of the treatment, not incidental background.

By the end of the 1950s, LSD was widely regarded in North America as a “miracle cure for alcohol addiction.” The reported success in Saskatchewan led the Government of Saskatchewan to help make LSD therapy a standard treatment option for alcoholics in the province. This history supplies the larger clinical and institutional context for Zeff's indexed program. It also cautions against treating the promise of LSD therapy as a settled result: enthusiasm was substantial, but clinicians disagreed over what the treatment's success demonstrated and how reliably it could be reproduced.

Toronto replication and the dispute over results

In the early 1960s, the Addiction Research Foundation in Toronto set out to replicate the Saskatchewan trials with tighter controls. Its clinicians sought to isolate the drug's effects from other influences. They administered LSD in neutral rooms and instructed staff not to engage with participants during their sessions, except to give them an extensive questionnaire. Some volunteers were restrained or blindfolded, or both. The results did not match those reported by Osmond and Hoffer, and several participants underwent terrifying experiences—the episodes that came to be known as bad trips.

The replication sharpened rather than resolved the disagreement. Critics could point to the poorer results under rigorous control as evidence that LSD treatment did not work as well as its advocates claimed. Supporters could point to the contrast in conditions and argue that the absence of attention and a supportive environment had undermined the therapy. The book presents both conclusions as partly valid: the treatment's apparent effects could not be separated cleanly from the setting in which it was delivered. For a program concerned with alcohol dependence, this methodological dispute was central, because it challenged the idea that the drug could be assessed independently of the therapeutic relationship and session environment.

Hubbard and the limits of the record

The index's cross-reference between Zeff and Al Hubbard places the two within the book's account of psychedelic treatment, but the available passages do not specify the nature of their association. A related note records that Hubbard's name appeared on one scientific paper, coauthored with colleagues at Hollywood Hospital: “The Use of LSD-25 in the Treatment of Alcoholism and Other Psychiatric Problems,” published in 1961. The paper's title establishes that Hubbard participated in a published account of LSD treatment for alcoholism and other psychiatric problems; it does not establish that Zeff coauthored it, worked at the hospital, or shared its methods.

The record thus leaves Zeff's individual contribution less fully described than the broader controversy surrounding psychedelic treatment for alcoholism. What it does make visible is the question that shaped that controversy: whether a therapeutic outcome belonged to the pharmacological action of LSD alone, or to an experience formed jointly by the drug, the patient, and the conditions of care. The history around Zeff's program makes that question consequential without supplying enough detail to attribute a particular answer or outcome to Zeff himself.